Affiliation:
1. Johnson and Johnson Pharmaceutical Research and Development LLC, Raritan, New Jersey
Abstract
ABSTRACT
Doripenem, a parenteral carbapenem, exhibited high affinity for penicillin-binding protein 2 (PBP2) and PBP3 in
Pseudomonas aeruginosa
and PBP2 in
Escherichia coli
, the primary PBPs whose inhibition leads to cell death. This PBP affinity profile correlates with the broad-spectrum gram-negative activity observed with doripenem.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
110 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synthesis, antimicrobial evaluation, and molecular docking studies of Mannich base analogs derived from 2,3-dihydro-1,3,4-oxadiazole-2(3H)-thione scaffold;Chemical Papers;2024-07
2. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
Escherichia coli
strains producing broad-spectrum β-lactamases;Antimicrobial Agents and Chemotherapy;2024-04-03
3. Carba PBP: a novel penicillin-binding protein-based lateral flow assay for rapid phenotypic detection of carbapenemase-producing
Enterobacterales;Journal of Clinical Microbiology;2024-02-14
4. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?;European Journal of Clinical Microbiology & Infectious Diseases;2023-12-14
5. Monooxygenases and Antibiotic Resistance: A Focus on Carbapenems;Biology;2023-10-09